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A B S T R A C T
Purpose
Chemoradiotherapy has been considered standard treatment for patients with limited-stage
aggressive lymphoma on the basis of trials conducted before the introduction of the International
Prognostic Index. To evaluate this approach in elderly patients with low-risk localized lymphoma,
we conducted a trial comparing chemoradiotherapy with chemotherapy alone.
Patients and Methods
Previously untreated patients older than 60 years with localized stage I or II histologically
aggressive lymphoma and no adverse prognostic factors of the International Prognostic Index
were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone
with four cycles of CHOP (277 patients).
Results
With a median follow-up time of 7 years, event-free and overall survival did not differ between the
two treatment groups (P .6 and P .5, respectively). The 5-year estimates of event-free survival
were 61% for patients receiving chemotherapy alone and 64% for patients receiving CHOP
plus radiotherapy; the 5-year estimates of overall survival were 72% and 68%, respectively. In
a multivariate analysis, overall survival was affected by stage II disease (P  .001) and male
sex (P  .03).
Conclusion
In this large prospective study, CHOP plus radiotherapy did not provide any advantage over CHOP
alone for the treatment of low-risk localized aggressive lymphoma in elderly patients.
J Clin Oncol 25:787-792. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Radiation therapy, often after surgical staging, was
the standard treatment for patients with limited-
stage aggressive lymphoma until the late 1970s, pro-
viding rates of 5-year disease-free survival of less
than 50%.1 This approach subsequently evolved to
the addition of chemotherapy to involved-field ra-
diotherapy to avoid laparotomy, increase systemic
control of disease, and reduce the size of irradiation
fields.2 Because good results were also achieved with
chemotherapy alone,3 these two strategies were
used4 until the finding by Miller et al5 of the superi-
ority of three cycles of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (CHOP) followed
by involved-field radiotherapy compared with eight
cycles of CHOP alone with regard to survival. Of
note, patients enrolled onto this study were hetero-
geneous with regard to prognostic factors such as
age and serum lactate dehydrogenase level.
To determine the role of radiotherapy, the
Groupe d’Etude des Lymphomes de l’Adulte (GELA)
initiated, in 1993, a prospective randomized study
comparing four cycles of standard CHOP alone with
four cycles of CHOP followed by involved-field ra-
diotherapy. The study was conducted in a homoge-
neous population of elderly patients with localized
aggressive lymphoma and no adverse prognostic
factors as defined by the age-adjusted International
Prognostic Index.6 The results are presented here
with a median follow-up time of 7 years.
PATIENTS AND METHODS
Patients
Patients had to be older than 60 years and were re-
quired to have newly diagnosed aggressive lymphoma
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(International Working Formulation groups7: diffuse mixed, diffuse large-
cell, and immunoblastic and updated Kiel subgroup8: anaplastic) and to
present without any of the adverse prognostic factors of the age-adjusted
International Prognostic Index6 (eg, elevated lactate dehydrogenase level, per-
formance status  1, and Ann Arbor stage III or IV). Exclusion criteria
included positive serology for HIV and human T lymphotropic virus type I,
transformation of previous indolent lymphoma, primary cerebral lymphoma,
previous organ transplantation, concomitant or previous cancer (except in
situ cervical carcinoma), liver or kidney failure, and cardiac contraindication
to doxorubicin. Intestinal lymphoma, which could not be encompassed safely
in a radiation field, was also excluded from the study.
Histology and Immunophenotype
Central review was conducted by at least two pathologists from GELA,
and the International Working Formulation7 and Kiel grouping8 used at the
time of entering patients onto the study was then reclassified according to the
WHO classification.9
Staging
The extent of the disease was evaluated by physical examination; com-
puted tomography of the chest, abdomen, and pelvis; CSF examination; bone
marrow biopsy; and other investigational procedures depending on the clini-
cal symptoms. Patients were staged on the basis of Ann Arbor classification.
Stage I was defined as an involvement of a single lymph node region or
extranodal site, and stage II included involvement of two or more node regions
or involvement of an extranodal site and one or more adjacent node regions on
the same side of the diaphragm. Tumor measurements were obtained before
biopsy, and bulky disease was defined as any mass 10 cm or more in maximal
diameter. Performance status was assessed according to the Eastern Coopera-
tive Oncology Group scale, and lactate dehydrogenase level was expressed as
the maximum to normal value ratio.6
Treatment
Patients were randomly assigned to treatment with either chemother-
apy alone or combined chemoradiotherapy. The chemotherapy-alone arm
consisted of four cycles of the CHOP regimen (doxorubicin 50 mg/m2,
cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 [up to a maximum
dose of 2 mg] on day 1, and prednisone 60 mg/m2 on days 1 to 5) repeated
at 21-day intervals. The combined arm consisted of four cycles of CHOP
repeated at 21-day intervals, followed in patients with complete or partial
response by involved-field radiotherapy beginning 1 month after the last
cycle of CHOP.
The prescribed dose of radiation was 40 Gy in 22 fractions of 1.8 Gy 5
days per week. Irradiated volumes encompassed involved nodal or extranodal
sites and adjacent uninvolved nodes. For example, the iliac or the supraclavic-
ular nodes were included if inguinal or cervical nodes were initially involved,
respectively. The whole Waldeyer’s ring or stomach had to be irradiated if any
part was involved, and irradiation of the uninvolved adjacent regional nodes
was recommended. Specific technical factors, such as optimal balistic combi-
nation of photons and/or electrons or energy, were determined by the treating
radiation oncologist. Dosimetric calculations were recommended at least bi-
dimensionally on the central axis and in two other in-field clinically relevant
areas. Radiotherapy data were prospectively reported in a specific case record
form and centrally reviewed for identification of protocol deviations.
In both arms, no dose adjustment of chemotherapy was planned
according to toxicity, but courses were postponed until leukocyte and
platelet counts increased to greater than 2,000 and 100,000/L, respec-
tively. Patients could receive granulocyte colony-stimulating factor at the
discretion of each investigator.
Assessment of Response
Response was evaluated 1 month after the completion of treatment,
according to the International Workshop criteria.10 A complete response was
defined as the disappearance of all clinical evidence of disease and of radiologic
abnormalities observed at diagnosis. An unconfirmed complete response was
defined as a complete response with some persisting radiologic abnormalities,
which in the aggregate had to be at least 75% smaller than the original abnor-
mality. A partial response was defined as the regression of tumor volumes by
more than 50%, and stable disease was defined as a lower response. Progressive
disease (growth of the initial lesion by  25% or the appearance of a new
lesion) during treatment was considered to indicate primary failure.
Statistical Analysis
Random assignment was stratified according to participating center and
the presence or absence of bulky disease. The primary end point was event-free
survival; the secondary end points were the response rate and overall survival.
Calculation of sample size was based on the primary end point. To detect a
change at 2 years of 10% (null hypothesis: 60%; alternative hypothesis: 70%),
we calculated that 650 patients (330 events) would be required to provide the
trial with 90% power at an overall 5% significance level. The trial began in
March 1993. After 500 patients had been enrolled, the data and safety moni-
toring committee undertook the planned interim analysis, which was com-
pleted in December 2001. Results indicated no significant difference in 5-year
event-free survival (chemotherapy alone, 67% v chemoradiotherapy, 62%;
P  .05). Because, at that time, there was growing evidence that rituximab
might dramatically improve chemotherapy efficacy in elderly patients with
aggressive lymphoma, the data and safety monitoring committee recom-
mended that the study be stopped. A total of 576 patients had been randomly
assigned and were observed to assess event-free survival. The revised power of
the study with 576 patients is 0.85.
Analyses included all of the enrolled patients and followed the intent-to-
treat principle. Patient characteristics and response rates were compared using
2 and Fisher’s exact tests. Event-free survival was measured from the date of
random assignment to primary failure, relapse, or death from any cause.
Overall survival was measured from the date of random assignment to the date
of death from any cause. Survival functions were estimated using the Kaplan-
Meier method11 and compared by log-rank test.12 Multivariate analyses were
performed using the Cox model for survival data.13
Differences between the results of comparative tests were considered
significant if the two-sided P  .05. All statistical analyses were performed
using SAS 9.1 software (SAS Institute, Cary, NC).
The study was designed by the GELA scientific committee and moni-
tored by the GELA coordinating center, which issued treatment allocation by
fax after confirmation of the patient eligibility. Case report forms collected at
participating centers were sent to the GELA centralized database and keyed in
twice for verification. Outliers and erroneous values were checked routinely.
Queries and onsite monitoring were used for final validation.
The trial was approved by the local committee on human investigations
and was conducted in accordance with a written assurance approved by the
local Department of Health and Human Services. All of the patients included
had to give informed consent to participate.
RESULTS
Patient Characteristics
Between March 1993 and June 2002, 576 patients were
enrolled at 65 participating centers; 277 were assigned to chem-
otherapy alone, and 299 were assigned to CHOP plus radiother-
apy. The characteristics of the patients did not differ between
the two treatment groups; entire clinical data were available in
96% of the enrolled patients, and histologic central review was
performed in 89% of patients (Table 1). Median age was 68 years
(range, 60 to 85 years). Bulky disease was present at random assign-
ment in 49 patients (8%). Sixty-five percent of the patients had stage I
disease. Extranodal involvement was found in half of the patients.
Diffuse large B-cell lymphoma was the most common subtype, occur-
ring in 80% of the patients.
Response to Treatment
A complete or unconfirmed complete response was observed in
89% of the patients treated with chemotherapy alone and in 91% of
Bonnet et al
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patients treated with chemoradiotherapy (Table 2). In each treatment
group, 94% of the patients received at least 80% of the theoretical
dose-intensity of doxorubicin and cyclophosphamide.
In the CHOP plus radiotherapy group, the median time from the
last cycle of chemotherapy to the beginning of radiotherapy was 35
days; 5% of patients started irradiation before 21 days, and 5% started
after 59 days. Ninety-six percent of the irradiated patients received a
dose of 36 to 44 Gy, and 77% received the recommended dose of 40
Gy. Thirty-five of the 299 allocated patients did not receive the
planned radiotherapy as a result of poor response (n  9) or death
after CHOP chemotherapy (n 3), medical decision (n 10), and
refusal (n 13).
Among the seven deaths that occurred during treatment (Table
2), five resulted from toxicity secondary to chemotherapy, and two
resulted from lymphoma progression. No life-threatening acute tox-
icity of radiotherapy was reported. Eight episodes (3%) of grade 3
infection were reported in the CHOP-alone group compared with 10
episodes (3%) of grade 3 and two episodes of grade 4 infection in the
chemoradiotherapy group.
Outcome
With a median follow-up time of 7 years, 252 events (primary
failure, relapse, or death) were observed (125 in the chemotherapy-
alone group and 127 in the chemoradiotherapy group). Event-free
survival did not differ between the groups (P  .6), with 5-year
estimates of 61% (95% CI, 55% to 66%) in the chemotherapy-alone
group and 64% (95% CI, 58% to 69%) in the chemoradiotherapy
group (Fig 1).
There were 145 relapses, 79 in the chemotherapy-alone group
and 66 in chemoradiotherapy group; median times to relapse were 14
and 17 months, respectively. In the chemotherapy-alone group, dis-
ease recurred in the initial site in 47% of patients who experienced
relapse, at a distant site in 37% of patients, and at both initial and
distant sites in 16% of patients. In the CHOP plus radiotherapy group,
disease recurred in the irradiation field in 21% of patients who expe-
rienced relapse, out of field in 66% of patients, and both in and out of
field in 13% of patients.
There were 215 deaths, 101 in the chemotherapy-alone group
and 114 in the CHOP plus radiotherapy group. Overall survival did
not significantly differ between the groups (P .5), with 5-year esti-
mates of 72% (95% CI, 66% to 77%) in the chemotherapy-alone
group and 68% (95% CI, 63% to 74%) in the chemoradiotherapy
group (Fig 2). In the subgroup of 247 patients older than 70 years, the
5-year overall survival rate was higher in patients treated with









Total No. of patients 277 299
Median age, years 69 68
Male sex 148 53 151 50
Bulky disease at random
assignment
21 8 28 9
Clinical characteristics
Information available 266 96 289 97
Stage
I 172 65 186 65
II 87 32 99 34
IV 7 3 4 1
Lactate dehydrogenase
Normal 261 98 281 97
Elevated 5 2 8 3
Performance status
0 191 72 211 73
1 74 27 75 26
2 1  1 3 1
Age-adjusted International
Prognostic Index scores
0 253 95 274 95
1 13 5 15 5
Extranodal involvement 139 52 135 46
Organ involved
Waldeyer’s ring and sinus 53 20 72 25
Stomach 29 11 18 6
Bone 11 4 10 3
Skin 9 3 7 2
Other† 37 14 28 10
Histologic findings
Centrally reviewed‡ 242 87 269 90
Eligible histology 218/242 90 250/269 93
Diffuse large B-cell lymphoma 187 77 223/269 83
Anaplastic large-cell
lymphoma
8 3 7 3
Nonanaplastic T/NK-cell
lymphoma
13 6 12 4
Unclassified aggressive
lymphoma
10 4 8 3
Inappropriate histology 24 10 19 7
Small lymphocytic lymphoma 5 2 1  1
Marginal zone lymphoma 2  1 0 0
Follicular lymphoma 5 2 6 2
Mantle cell lymphoma 5 2 2  1
Lymphoblastic lymphoma 1  1 1  1
Burkitt’s lymphoma 1  1 2  1
Hodgkin’s lymphoma 2  1 4 1
Carcinoma 2  1 1  1
Nonmalignant 1  1 2  1
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and pred-
nisone; NK, natural killer.
This was an exclusion criterion.
†Other categories include: breast, thyroid, testis, orbit, kidney, pancreas,
adrenal gland.
‡The classification of the WHO was used.













244 89 270 91
Partial response 8† 3 1  1
Stable disease 8 3 4 1
Primary failure 9 3 17 6
Death 4 1 3 1
Abbreviation: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Response was assessed 1 month after completion of treatment. Because of
missing data, response could not be assessed in four patients from the CHOP-alone
group and in four patients from the CHOP plus radiotherapy group.
†Protocol violation occurred in six patients with partial response who were given
additional radiotherapy by their physician.
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chemotherapy alone (69% v 58% in patients receiving chemora-
diotherapy), but this trend did not reach significance (P .2).
When analysis was restricted to patients who met eligible
histologic criteria, 5-year estimates of event-free and overall sur-
vivals were identical for both treatment arms. Event-free survival
estimates were 62% for CHOP alone compared with 63% for
chemoradiotherapy (P  .8), and the overall survival estimates
were 71% for CHOP alone compared with 68% for chemoradio-
therapy (P .6).
In a multivariate analysis of the 576 patients, overall sur-
vival was affected by stage II disease (P  .001; risk ratio, 1.9;
95% CI, 1.4 to 2.5) and male sex (P .03; risk ratio, 1.4; 95% CI,
1.0 to 1.8) but not by bulky disease (P .3); event-free survival
was affected only by stage II disease (P  .001; risk ratio, 1.8;
95% CI, 1.4 to 2.3). Of note, among the 576 patients, 5-year
event-free and overall survival rates were 70% and 76% for
patients with stage I disease, respectively, and 49% and 58% for
patients with stage II disease, respectively.
Among the 215 deaths, the cause could be documented in 212
patients (99 patients in the chemotherapy-alone group and 113
patients in the chemoradiotherapy group). Among the 212 docu-
mented deaths, 135 (64%) were related to lymphoma progression
(65 in the CHOP alone group and 70 in the chemoradiotherapy
group). Twenty-nine deaths (14%) occurred as a result of a second
cancer that developed in patients after their entry onto the study.
Nine of these second cancers were observed in the CHOP-alone
group, including one myelodysplasia; 20 occurred in the chemora-
diotherapy group, including one acute myelogenous leukemia and
three cancers within the irradiation field. At the time of death, these
29 patients with second cancer were in remission from their lym-
phoma. In the aggregate, 8 patients died from toxicity that oc-
curred during or after primary treatment, and three additional
patients died from toxicity related to salvage treatment for lym-
phoma relapse. Other causes of death in patients with lymphoma
in primary or secondary remission included cardiovascular disease
in 32 patients (16 patients in each treatment group), infection in
two patients, suicide in two patients, and hypereosinophilic syn-
drome in one patient. Of note, nonfatal late effects of radiotherapy
included persistent xerostomia in 36% of patients with Waldeyer’s
ring lymphoma and other events such as gastritis (three patients)
and ileitis (two patients).
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Fig 1. Event-free survival among 576 pa-
tients assigned to either chemotherapy
alone with four cycles of cyclophospha-
mide, doxorubicin, vincristine, and pred-
nisone (CHOP) or four cycles of CHOP plus
involved-field radiotherapy.
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Fig 2. Overall survival among 576 pa-
tients assigned to either chemotherapy
alone with four cycles of cyclophospha-
mide, doxorubicin, vincristine, and pred-
nisone (CHOP) or four cycles of CHOP plus
involved-field radiotherapy.
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DISCUSSION
This study of 576 patients is the only randomized trial comparing brief
chemotherapy alone consisting of four cycles of CHOP with the same
chemotherapy followed by consolidative involved-field radiotherapy.
The latter approach has been considered standard therapy for local-
ized disease14 since the study of Miller et al5 based on 400 patients with
4.4 years of median follow-up time. In the present study of patients
older than 60 years with low-risk stage I or II aggressive lymphoma and
with a median follow-up time of 7 years, we found that event-free and
overall survival estimates among patients treated with chemotherapy
alone did not differ from those observed among patients treated with
chemoradiotherapy. Of note, we observed a lack of difference in out-
come for the 49 patients with bulky disease, a condition in which
adjuvant radiotherapy is believed to optimally control local dis-
ease15,16; however, this must be interpreted cautiously because of the
small size of this subset of patients.
We selected our study population of elderly patients using the
age-adjusted International Prognostic Index, the widely used system
to stratify patients before therapy,6 thus providing a homogeneous
cohort of patients with regard to main prognostic parameters such as
age, lactate dehydrogenase level, and performance status. By contrast,
the patient sample in the study by Miller et al5 included half of patients
younger than 61 years and 20% of patients with an elevated lactate
dehydrogenase level. Of note, an update of this study with a longer
follow-up showed that survival curves ultimately converged as a result
of an excess of lymphoma relapses in the CHOP plus radiotherapy
group.17 Horning et al18 recently reported the results of a study with a
median follow-up of 12 years in which patients with limited-stage
aggressive lymphoma received consolidative radiotherapy after eight
cycles of CHOP; as in the study by Miller et al,5 the study population
was heterogeneous because it included young adult and elderly pa-
tients and possibly varying lactate dehydrogenase levels (not available
at diagnosis). Of note, radiotherapy did not affect survival despite
some marginal improvement in event-free survival. As commented by
the authors,18 radiotherapy provided good local control, but systemic
relapses remained the major cause of treatment failure. This is con-
firmed in our study because, although the majority of patients had
stage I disease, belonging to the very limited category described by
Miller,19 consolidative radiotherapy altered the pattern of localization
of relapses but did not decrease their overall rate compared with
CHOP alone.
With a median follow-up time of 7 years, we observed, as have
others,14 that second malignancies and cardiovascular disease re-
mained a significant cause of subsequent death in elderly patients with
lymphoma. Twenty-nine second cancers developed after patient en-
rollment onto the study. Nine second cancers were in the CHOP-
alone group, including one myelodysplasia; 20 occurred in the
chemoradiotherapy group but included only one acute myelogenous
leukemia and three cancers within the irradiation field. This is in
keeping with existing reports of a moderate risk of second malignancy
after brief CHOP chemotherapy plus involved-field radiotherapy.14,20
Our study demonstrates that chemotherapy with four cycles of
CHOP followed by consolidative radiotherapy, as administered in a
large-scale trial, is not superior to four cycles of CHOP alone in elderly
patients with low-risk localized aggressive lymphoma. Taking also
into account the results of our previous study in young adult patients
that showed an advantage of chemotherapy alone over chemoradio-
therapy,21 the GELA decided to abandon radiotherapy as first-line
treatment of localized aggressive lymphoma, with the advantage of
avoiding its late effects, especially in the frequently involved cervical
and Waldeyer’s ring regions.
To improve survival over the 72% 5-year rate observed in the
present study, a result which is in keeping with that of earlier cited
studies,5,18 it is reasonable to propose that such elderly patients with
localized B-cell aggressive lymphoma should be treated with a combi-
nation of CHOP and rituximab. This recommendation is based on the
results of the previous GELA study in elderly patients22 and of its
recent update23 in which the 5-year survival rate of patients with
low-risk stage II disease is estimated at more than 80% after eight
cycles of CHOP plus rituximab. Alternatively, a shorter immuno-
chemotherapy regimen followed by radiolabeled antibodies might be
a potential approach that deserves to be investigated.
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